Table 2.
Univariate Cox proportional hazard model of overall survival by each variable
| Baseline Characteristics | HR (95% CI) | p-value | Chemotherapy | HR (95% CI) | p-value |
|---|---|---|---|---|---|
| Age | 0.978 (0.958–1.000) | 0.047 | Regimen | 0.941 | |
| Gender | 0.111 | Platinum + FU | 1 | ||
| Male | 1 | Taxane + FU | 1.336 (0.643–2.776) | 0.437 | |
| Female | 1.464 (0.916–2.339) | Platinum + Taxane + FU | 1.116 (0.569–2.188) | 0.750 | |
| cT stage | 0.734 | Taxane + Platinum | 1.003 (0.511–1.969) | 0.994 | |
| Serosa negative | 1 | Others | 0.904 (0.354–2.306) | 0.832 | |
| Serosa positive | 1.107 (0.616–1.988) | Best response | |||
| cN stage | 0.743 | Overall | 0.201 | ||
| N0/N1 | 1 | CR/PR | 1 | ||
| N2/N3 | 1.109 (0.597–2.061) | SD/PD | 1.359 (0.849–2.175) | ||
| Type of distant metastasis | 0.065 | Local region | 0.576 | ||
| Peritoneal carcinomatosis | 1 | CR/PR | 1 | ||
| Liver metastasis | 0.407 (0.166–0.994) | 0.049 | SD/PD | 1.142 (0.717–1.817) | |
| Distant LN metastasis | 1.025 (0.590–1.780) | 0.930 | Metastatic site | 0.013 | |
| Krukenberg tumor | 4.423 (1.004–19.487) | 0.049 | CR/PR | 1 | |
| Any combination | 0.900 (0.467–1.735) | 0.753 | SD/PD | 2.105 (1.171–3.783) | |
| NLR (Neut/lympho) | 1.349 (0.837–2.177) | 0.219 | Preop. response | ||
| SII (PLT*Neut/lympho) | 1.252 (0.776–2.019) | 0.357 | Overall | 0.635 | |
| Albumin | 0.986 | CR/PR | 1 | ||
| low | 1 | SD/PD | 1.119 (0.704–1.777) | ||
| normal | 1.006 (0.480–2.108) | Local region | 0.875 | ||
| CR/PR | 1 | ||||
| SD/PD | 0.963 (0.602–1.540) | ||||
| Metastatic site | 0.020 | ||||
| CR/PR | 1 | ||||
| SD/PD | 1.850 (1.103–3.103) | ||||
| Number of Cycles of Chemotherapy | 0.970 (0.930–1.013) | 0.167 | |||
| ≤ 6 cycles | 1 | 0.746 | |||
| > 6 cycles | 0.925 (0.578–1.480) | ||||
| Pre-Operation | HR (95% CI) | p-value | Surgical Outcomes | HR (95% CI) | p-value |
| BMI | 0.004 | Peritoneal infiltration | 0.002 | ||
| Normal | 1 | No | 1 | ||
| Underweight | 3.538 (1.607–7.789) | 0.002 | Yes | 2.181 (1.343–3.540) | |
| Overweight & obese | 1.073 (0.647–1.778) | 0.786 | Metastasectomy | 0.252 | |
| Change in CEA level | 0.009 | No | 1 | ||
| Stable | 1 | Yes | 1.507 (0.747–3.039) | ||
| Improved | 0.410 (0.193–0.868) | 0.020 | Extent of gastrectomy | 0.008 | |
| Worse | 4.174 (1.255–13.881) | 0.020 | TG | 1 | |
| NA | 0.856 (0.446–1.646) | 0.642 | DG | 0.521 (0.322–0.842) | |
| Change in CA19–9 level | 0.399 | Extent of LND | 0.402 | ||
| Stable | 1 | < D2 | 1 | ||
| Improved | 1.020 (0.437–2.381) | 0.963 | ≥ D2 | 0.802 (0.480–1.343) | |
| Worse | 0.907 (0.282–2.911) | 0.869 | Complete Macroscopic Resection | < 0.001 | |
| NA | 0.580 (0.309–1.089) | 0.090 | Yes | 1 | |
| Pre_op cT stage | 0.069 | No | 2.348 (1.471–3.748) | ||
| Serosa negative | 1 | pT stage | 0.002 | ||
| Serosa positive | 1.537 (0.967–2.444) | Serosa negative (pT1–3) | 1 | ||
| Pre_op cN stage | 0.567 | Serosa positive (pT4a/b) | 2.109 (1.311–3.393) | ||
| N0/N1 | 1 | pN stage | 0.121 | ||
| N2/N3 | 1.155 (0.705–1.894) | pN0/N1 | 1 | ||
| Time interval to surgery | 0.926 | pN2/N3 | 1.480 (0.901–2.430) | ||
| ≤ 24 weeks | 1 | Lauren classification | 0.013 | ||
| > 24 weeks | 0.926 (0.584–1.468) | Intestinal | 1 | ||
| Diffuse | 1.960 (1.204–3.190) | 0.007 | |||
| Others | 0.867 (0.361–2.079) | 0.748 | |||
| Postoperative chemotherapy | 0.172 | ||||
| No | 1 | ||||
| Yes | 1.629 (0.809–3.281) |
LN lymph node, NLR neutrophil lymphocyte ratio, SII systematic immune-inflammation index, CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, TG total gastrectomy, DG distal gastrectomy, LND lymph node dissection, FU fluoropyrimidine
The bold represents statistical significance